

## Clinical Policy: Naxitamab-gqgk (Danyelza)

Reference Number: LA.PHAR.523

Effective Date:

Last Review Date: 05.01.23

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Naxitamab-gqgk (Danyelza®) is a glycolipid disialoganglioside (GD2)-binding recombinant humanized monoclonal IgG1 antibody.

### FDA Approved Indication(s)

Danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\*

---

*\*This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).*

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections® that Danyelza is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Neuroblastoma (must meet all):

1. Diagnosis of high-risk neuroblastoma;
2. Disease is relapsed or refractory;
3. Disease is occurring in the bone or bone marrow;
4. Prescribed by or in consultation with an oncologist;
5. Age  $\geq$  1 year;
6. Prescribed in combination with GM-CSF (e.g., Leukine®);\*  
*\*Prior authorization may be required for Leukine*
7. Member has demonstrated a partial response, minor response, or stable disease to prior therapy (*see Appendix B for examples*);
8. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 150 mg (4 vials) per day for 3 days of each 4-week treatment cycle;

## CLINICAL POLICY

### Naxitamab-gqgk

- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:** 6 months

#### **B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

## **II. Continued Therapy**

#### **A. Neuroblastoma** (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Danyelza for a covered indication and has received this medication for at least 28 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 150 mg (4 vials) per day for 3 days of each 4- or 8-week treatment cycle;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:** 12 months

#### **B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

## **III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid, or evidence of coverage documents.

## **IV. Appendices/General Information**

## CLINICAL POLICY

### Naxitamab-gqgk

#### Appendix A: Abbreviation/Acronym Key

COG: Children's Oncology Group  
 FDA: Food and Drug Administration  
 GD2: glycolipid disialoganglioside  
 INRG: International Neuroblastoma Risk Group

INRGSS: International Neuroblastoma Risk Group Staging System  
 INSS: International Neuroblastoma Staging System  
 GM-CSF: granulocyte-macrophage colony-stimulating factor

#### Appendix B: Therapeutic Alternatives

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/Maximum Dose
cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, topotecan	Used in various combinations in variable dosing regimens	Varies
Unituxin <sup>®</sup> (dinutuximab), isotretinoin, GM-CSF	Used in various combinations in variable dosing regimens	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): history of hypersensitivity reaction to naxitamab-gqgk
- Boxed warning(s): serious infusion-related reactions and neurotoxicity

#### Appendix D: General Information

- Defining “high-risk” neuroblastoma: The Children's Oncology Group (COG) risk group system was initially based on the International Neuroblastoma Staging System (INSS) staging system, but is now transitioning to using the International Neuroblastoma Risk Group Staging System (INRGSS), along with the major prognostic factors to place children into 3 different risk groups: low, intermediate, and high. High-risk neuroblastoma patients, per COG, are:
  - Stage 2A or 2B disease and MYCN amplification
  - Stage 3 disease and MYCN amplification
  - Stage 3 disease in children age 18 months or older, no MYCN amplification, and unfavorable histopathology
  - Stage 4 disease in children younger than 12 months and MYCN amplification
  - Stage 4 disease in children between 12 months and 18 months with MYCN amplification, and/or diploidy, and/or unfavorable histology
  - Stage 4 disease in children 18 months or older
  - Stage 4S disease and MYCN amplification

## CLINICAL POLICY

### Naxitamab-gqgk

- International Neuroblastoma Risk Group (INRG) classification is a newer system that is now being used to help researchers in different countries compare results and work together to find the best treatments. This system is based on the newer INRGSS staging system, as well as many of the prognostic factors listed in the staging section, such as: the child's age, tumor histology, presence or absence of MYCN gene amplification, and presence of the 11q aberration, and DNA ploidy. The INRG classification uses these factors to put children into 16 different pre-treatment groups (lettered A through R). Each pre-treatment group falls into 1 of 4 overall risk groups listed below. This system will most likely be used in addition to the COG Risk Classification system in the United States.
  - Very low risk
  - Low risk
  - Intermediate risk
  - High risk

#### V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Neuroblastoma	<p>3 mg/kg/day IV on Days 1, 3, and 5 of each 28-day treatment cycle.</p> <p>Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks.</p> <p>Subsequent cycles may be repeated every 8 weeks.</p>	150 mg/day

#### VI. Product Availability

Injection solution in a single-dose vial: 40 mg/10 mL

#### VII. References

1. Danyelza Prescribing Information. New York, NY; November 2020. Available at: <https://labeling.ymabs.com/danyelza>. Accessed October 24, 2022.
2. American Cancer Society. Treating neuroblastoma. Last revised April 28, 2021. Available at: <https://www.cancer.org/content/dam/CRC/PDF/Public/8761.00.pdf>. Accessed October 24, 2022.
3. American Cancer Society. Neuroblastoma early detection, diagnosis, and staging. Last revised April 28, 2021. Available at: <https://www.cancer.org/content/dam/CRC/PDF/Public/8760.00.pdf>. Accessed October 24, 2022.
4. Cancer.net. Neuroblastoma – Childhood: Stages and Groups. Available at: <https://www.cancer.net/cancer-types/neuroblastoma-childhood/stages-and-groups>. Accessed October 24, 2022.

## CLINICAL POLICY

### Naxitamab-gqgk

5. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed September 14, 2021.

#### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9348	Injection, naxitamab-gqgk, 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	05.01.23	

#### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

## CLINICAL POLICY

### Naxitamab-gqgk

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2023 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.